Strong early U.S. YORVIPATH® launch with 908 prescriptions as of Feb. 7, 2025; YORVIPATH full year 2024 revenue of €28.7 million - Following pre-NDA meeting with FDA, on track to submit TransCon CNP ...

Q4 2024 Earnings Conference Call February 14, 2025 10:00 AM ETCompany ParticipantsAmy Hopkins - VP, IRPaul McDermott ...

Captain America: Brave New World marks the penultimate movie release of Phase 5 of the MCU which marks the midway point of The Multiverse Saga.

Astellas is shifting its investment focus toward more established modalities and later-stage opportunities, its chief ...

The company is now expecting 2025 revenue to range from $1.5 billion to $2.5 billion, with a midpoint of $2.0 billion, while FactSet is expecting $2.4 billion. Most of that will come in the second ...

Reports fourth quarter revenues of $1.0 billion, GAAP net loss of $(1.1) billion and GAAP EPS of $(2.91); loss includes approximately $0.2 billion of non-cash charges related to manufacturing resizing ...

Novartis' strong drug pipeline and financials support an 11% annual return by 2027. Learn why NVS stock offers 33% return ...

Kinross Gold reported increased adjusted net earnings and a record free cash flow in 2024, as the company works toward proceeding with mining at the Redbird open pit at the ...

Norwegian land-based salmon producer Salmon Evolution recently posted its best fourth-quarter results to date.

HC Wainwright reissued their buy rating on shares of Lineage Cell Therapeutics (NYSEAMERICAN:LCTX – Free Report) in a report released on Tuesday morning,Benzinga reports. The firm currently has a ...

Astera Labs Inc (NASDAQ:ALAB) shares are trading lower Tuesday on the heels of the company's fourth-quarter financial results ...

Aker Solutions' revenue rose 43% in the fourth quarter of 2024, and the company expects a solid order backlog in 2025 ...